Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2009

01-10-2009 | Preclinical Study

Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy

Authors: Laura Papi, Anna Laura Putignano, Caterina Congregati, Ines Zanna, Francesco Sera, Doralba Morrone, Mario Falchetti, Marco Rosselli Del Turco, Laura Ottini, Domenico Palli, Maurizio Genuardi

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Login to get access

Abstract

Background Germline mutations in the BRCA1 and BRCA2 tumour-suppressor genes predispose to early-onset breast and ovarian cancer. Although both genes display a highly heterogeneous mutation spectrum, a number of alterations recur in some populations. Only a limited number of founder mutations have been identified in the Italian population so far. Objective To investigate the spectrum of BRCA1/BRCA2 mutations in a set of families originary from the Central–Eastern part of Tuscany and to ascertain the presence of founder effects. We also wanted to approximate the age of the most frequent BRCA1 founder mutation. Results Overall, four distinct BRCA1 mutations accounted for a large fraction (72.7%) of BRCA1-attributable hereditary breast/ovarian cancer in families originary from this area. We identified common haplotypes for two newly recognised recurrent BRCA1 mutations, c.3228_3229delAG and c.3285delA. The c.3228_3229delAG mutation was estimated to have originated about 129 generations ago. Interestingly, male breast cancer cases were present in 3 out of 11 families with the c.3228_3229delAG mutation. Conclusions The observation that a high proportion of families with BRCA1 alterations from Central–Eastern Tuscany harbours a limited number of founder mutations can have significant impact on clinical management of at risk subjects from this area. In addition, the identification of a large set of families carrying an identical mutation that predisposes to breast and ovarian cancer provides unique opportunities to study the effect of other genetic and environmental factors on penetrance and disease phenotype.
Literature
2.
go back to reference Baudi F, Quaresima B, Grandinetti C et al (2001) Evidence of a founder mutation of BRCA1 in a highly homogeneous population from Southern Italy with breast/ovarian cancer. Hum Mutat 18:163–164. doi:10.1002/humu.1167 PubMedCrossRef Baudi F, Quaresima B, Grandinetti C et al (2001) Evidence of a founder mutation of BRCA1 in a highly homogeneous population from Southern Italy with breast/ovarian cancer. Hum Mutat 18:163–164. doi:10.​1002/​humu.​1167 PubMedCrossRef
7.
8.
go back to reference Ottini L, Rizzolo P, Zanna I et al (2008) BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in Central Italy. Breast Cancer Res Treat. doi:10.1007/s10549-008-0194-z Ottini L, Rizzolo P, Zanna I et al (2008) BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in Central Italy. Breast Cancer Res Treat. doi:10.​1007/​s10549-008-0194-z
10.
11.
go back to reference Bergman A, Einbeigi Z, Olofsson U et al (2001) The western Swedish BRCA1 founder mutation 3171ins5; a 3.7cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. Eur J Hum Genet 9:787–793. doi:10.1038/sj.ejhg.5200704 PubMedCrossRef Bergman A, Einbeigi Z, Olofsson U et al (2001) The western Swedish BRCA1 founder mutation 3171ins5; a 3.7cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. Eur J Hum Genet 9:787–793. doi:10.​1038/​sj.​ejhg.​5200704 PubMedCrossRef
12.
go back to reference Beloch KJ (1995) Storia della popolazione d’Italia. In: Del Panta L, Sonnino E (eds) Le Lettere, Firenze, pp xxxii, 695 Beloch KJ (1995) Storia della popolazione d’Italia. In: Del Panta L, Sonnino E (eds) Le Lettere, Firenze, pp xxxii, 695
13.
go back to reference Ford D, Easton DF, Peto J (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457–1462PubMed Ford D, Easton DF, Peto J (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457–1462PubMed
14.
go back to reference Whittemore AS, Gong G, Itnyre J (1997) Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three US population-based case-control studies of ovarian cancer. Am J Hum Genet 60:496–504PubMed Whittemore AS, Gong G, Itnyre J (1997) Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three US population-based case-control studies of ovarian cancer. Am J Hum Genet 60:496–504PubMed
15.
go back to reference Risch HA, McLaughlin JR, Cole DE et al (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98:1694–1706PubMedCrossRef Risch HA, McLaughlin JR, Cole DE et al (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98:1694–1706PubMedCrossRef
16.
go back to reference Whittemore AS, Gong G, John EM et al (2004) Prevalence of BRCA1 mutation carriers among US non-Hispanic whites. Cancer Epidemiol Biomarkers Prev 13:2078–2083PubMed Whittemore AS, Gong G, John EM et al (2004) Prevalence of BRCA1 mutation carriers among US non-Hispanic whites. Cancer Epidemiol Biomarkers Prev 13:2078–2083PubMed
19.
go back to reference Ottini L, Masala G, D’Amico C et al (2003) BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res 63:342–347PubMed Ottini L, Masala G, D’Amico C et al (2003) BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res 63:342–347PubMed
21.
go back to reference Easton DF, Steele L, Fields P et al (1997) Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12–13. Am J Hum Genet 61:120–128. doi:10.1086/513891 PubMedCrossRef Easton DF, Steele L, Fields P et al (1997) Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12–13. Am J Hum Genet 61:120–128. doi:10.​1086/​513891 PubMedCrossRef
23.
go back to reference Friedman LS, Gayther SA, Kurosaki T et al (1997) Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 60:313–319PubMed Friedman LS, Gayther SA, Kurosaki T et al (1997) Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 60:313–319PubMed
24.
go back to reference Csokay B, Udvarhelyi N, Sulyok Z et al (1997) High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 59:995–998 Csokay B, Udvarhelyi N, Sulyok Z et al (1997) High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 59:995–998
26.
go back to reference Brose MS, Rebbeck TR, Calzone KA et al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365–1372PubMed Brose MS, Rebbeck TR, Calzone KA et al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365–1372PubMed
27.
go back to reference Anagnostopoulos T, Pertesi M, Konstantopoulou I et al (2008) G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history. Breast Cancer Res Treat 110:377–385. doi:10.1007/s10549-007-9729-y PubMedCrossRef Anagnostopoulos T, Pertesi M, Konstantopoulou I et al (2008) G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history. Breast Cancer Res Treat 110:377–385. doi:10.​1007/​s10549-007-9729-y PubMedCrossRef
29.
go back to reference Peelen T, van Vliet M, Petrij-Bosch A et al (1997) A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 60:1041–1049PubMed Peelen T, van Vliet M, Petrij-Bosch A et al (1997) A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 60:1041–1049PubMed
30.
go back to reference Neuhausen SL, Mazoyer S, Friedman L et al (1996) Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet 58:271–280PubMed Neuhausen SL, Mazoyer S, Friedman L et al (1996) Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet 58:271–280PubMed
31.
go back to reference Machado PM, Brandão RD, Cavaco BM et al (2007) Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 25:2027–2034. doi:10.1200/JCO.2006.06.9443 PubMedCrossRef Machado PM, Brandão RD, Cavaco BM et al (2007) Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 25:2027–2034. doi:10.​1200/​JCO.​2006.​06.​9443 PubMedCrossRef
Metadata
Title
Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy
Authors
Laura Papi
Anna Laura Putignano
Caterina Congregati
Ines Zanna
Francesco Sera
Doralba Morrone
Mario Falchetti
Marco Rosselli Del Turco
Laura Ottini
Domenico Palli
Maurizio Genuardi
Publication date
01-10-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0190-3

Other articles of this Issue 3/2009

Breast Cancer Research and Treatment 3/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine